Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. ALL arises from the malignant transformation of progenitor B-and T-cells in the bone marrow into leukemic cells, but the mechanisms underlying this transformation are not well understood. Recent technical advances and decreasing costs of methods for high-throughput DNA sequencing and SNP genotyping have stimulated systematic studies of the epigenetic changes in leukemic cells from pediatric ALL patients. The results emerging from these studies are increasing our understanding of the epigenetic component of leukemogenesis and have demonstrated the potential of DNA methylation as a biomarker for lineage and subtype classification, prognostication, and disease progression in ALL. In this review, we provide a concise examination of the epigenetic studies in ALL, with a focus on DNA methylation and mutations perturbing genes involved in chromatin modification, and discuss the future role of epigenetic analyses in research and clinical management of ALL.
Acute lymphoblastic leukemia (ALL)
Acute lymphoblastic leukemia (ALL) is the most common form of pediatric cancer. Structural chromosomal rearrangements, which can lead to expressed fusion genes, are together with clinical features such as white blood cell count at diagnosis and minimal residual disease status, the main basis for diagnosis, risk stratification, and prognosis of pediatric ALL [1] . Patients with ALL are classified into genetic subtypes based on the occurrence of recurrent chromosomal abnormalities detected by karyotyping (G-banding), fluorescent in situ hybridization (FISH), and/or polymerase chain reaction (PCR) amplification. ALL arises from hematopoietic cells in either the B-cell precursor (BCP-ALL) or T-cell lineages (T-ALL). Both the BCP-ALL and T-ALL immunophenotype groups comprise multiple subtypes defined by chromosomal alterations that are believed to be the leukemia-initiating lesions [1] . In most protocols, the important subtypes for prognosis of ALL are T-ALL and the BCP-ALL subtypes high hyperdiploidy (HeH), t (12;21)ETV6-RUNX1, t(1;19)E2A-PBX1, t(9;22)BCR-ABL1, dic (9;20) , iAMP21, hypodiploidy (< 45 chr), and KMT2A (also known as MLL1) rearrangements.
However, 20% of newly diagnosed BCP-ALL cases do not belong to any of the known genetic subtypes. These patients, whose subtype is referred to as B-other, are limited to clinical and minimal residual disease data for informing treatment decisions and also typically lack leukemia-specific genetic changes that can be used for disease monitoring during treatment [2] . During 2016-2017, several previously unknown recurrent genomic rearrangements involving the DUX4, ZNF384, or MEF2D genes were discovered in the B-other subgroup [3, 4, 5, 6] . These and other emerging subtypes of ALL have been reviewed in detail elsewhere [1] .
Normal hematopoietic cell development requires tightly controlled regulation of DNA methylation, chemical modification of histones, and expression of non-coding RNAs, all of which may be deregulated during leukemic transformation. DNA methylation is by far the most well characterized epigenetic modification, and is involved in the regulation of gene expression, maintenance of genome stability, and cellular differentiation. Many studies have implicated aberrant epigenetic regulation in the pathogenesis, treatment outcome and recurrence of ALL. This review will summarize and discuss the functions and consequences of epigenetic alterations with a focus on DNA methylation and somatic mutational signatures in epigenetic regulating genes in pediatric ALL as elucidated by recent studies.
Technology for DNA methylation analysis
The human genome contains 28 million CpG sites that are targets for DNA methylation. The discovery of epigenetic biomarkers has significantly expanded owing to the development of methods for interrogating DNA methylation on a genome-wide scale using hybridization microarrays and next generation sequencing (NGS). Methods for detecting DNA methylation can be divided into three broad classes; those involving (I) enrichment of methylated genomic positions, (II) digestion with methylation-sensitive restriction enzymes, and (III) utilization of sodium bisulfite treatment, which converts unmethylated cytosine residues into thymine, while methylated cytosines are protected against conversion. These approaches vary in many aspects, such as required DNA input, degree of genomic resolution and coverage, and ability of quantification. Thus, when comparing results from different DNA methylation studies the method(s) used for determination of DNA methylation levels should be considered. Here, we will briefly summarize methodologies applied for genome-wide DNA methylation analysis in studies of ALL patient cohorts.
The earliest genome-wide methods implemented in ALL involved enrichment of methylated DNA fragments, either by a combination of methylation specific restriction enzyme digestion and PCR [7, 8] or immunoprecipitation of methylated DNA fragments [9] , followed by reading out the results using hybridization microarrays. The relative abundance of the enriched DNA regions is an estimate of the amount of cytosine methylation at any given region of the genome that is represented by probes on the array. The strength of these methods is that they cover relatively large genomic regions, but a limitation is that enrichment methods do not provide single-base resolution of DNA methylation at individual CpG sites.
Sodium bisulfite treatment of DNA enables measurement of the methylation status of individual cytosine residues at a single-base resolution. Targeted analysis of DNA methylation in bisulfite-treated DNA can in principle be performed by any SNP genotyping method. The MassArray system (Agena, formerly Sequenom) has been used during more than two decades because it allows robust quantification of the DNA methylation levels at targeted CpG sites [10] . A custom designed Golden Gate assay (Illumina) for 1536 CpG sites in candidate gene promoter regions was used in an early study of allele-specific regulation of gene expression by DNA methylation in primary ALL cells [11] . Today the most frequently used methods with capacity of single-base resolution of bisulfite-converted DNA with high-throughput analysis of many CpG sites and samples in parallel are the Infinium BeadChip assays (Illumina). The BeadChip assays interrogate the methylation status of cytosine residues by genotyping cytosine or thymine (methylated vs unmethylated cytosine residues) using a predetermined set of probes in a microarray format. The Infinium assays offer quantitative measurement of DNA methylation and have been launched with increasing numbers of target CpG sites over the last decade, starting with the HumanMethylation 27 K BeadChip (27k array) that mostly targeted CpG islands [12] , followed by the HumanMethylation 450 K (450k array) [13] and Infinium MethylationEPIC (850k array) BeadChips [14] , which in addition to CpG islands and genes, also assay CpG island shores, gene bodies, enhancers, and other non-coding genomic regions. The BeadChips provide a user friendly and straightforward approach for analyzing hundreds of thousands of CpG sites in many samples at a relatively low cost.
Although the targeted approaches using BeadChip assays for DNA methylation analysis offer advantages for analysis of large patient cohorts, they target only up to 3% of the 28 million CpG sites in the genome, while complete genome-wide DNA methylome maps can only be achieved by whole-genome sequencing of bisulfite-treated DNA (WGBS) [15] . Several approaches for creating WGBS libraries from genomic DNA in combination with bisulfite conversion followed by sequencing by next generation sequencing (NGS) have been described. The different WGBS library construction approaches may affect the genomic coverage and the accuracy of the methylation calling, as shown in a recent bench-marking study [16] . Although the reagent costs for whole-genome sequencing (WGS) are decreasing, the large amount of DNA required in the first generation WGBS methods together with the high cost and limited availability of user-friendly methods for analysis of the WGBS data have so far limited the size of the patients cohorts subjected to WGBS in ALL [17, 18] .
A potential source of error in interpretation of DNA methylation levels using bisulfite conversion is that both 5-methyl cytosine (5mC) and 5-hyroxylmethyl cytosine (5hmC) are read as cytosine, and thus cannot be discriminated. This drawback of bisulfite treatment can be circumvented by introduction of an oxidation step in the bisulfite treatment procedure [19] . From a biological point of view discrimination between 5hmC and 5mC at single-base resolution in DNA is desirable because 5hmC may have opposite functions to 5mC, for example by how it affects gene expression. Demethylation of 5hmC occurs as a result of oxidation of 5mC by enzymes of the TET (ten-eleven translocation) family [20] . TET mutations are rare, but have been detected in about 1% of ALL cases [21, 22] . Mutations in the TET2 enzyme are associated with reduced 5hmC levels in acute myeloid leukemia [23] , however it is unclear whether 5hmC occurs in ALL cells and hence it is not known to what extent 5hmC may influence the results of the bisulfite conversion-based assays commonly used to study DNA methylation in ALL.
There are several factors that can affect the interpretation of quantitative DNA methylation in the analyses of ALL cells, such as the sample number in the studies, tumor heterogeneity due to presence of DNA from subclonal populations of leukemic blasts, and presence of DNA from normal hematopoietic or blood cells within the leukemic DNA samples. It is difficult to experimentally identify and define epigenetic states within a population of bulk cells because of the heterogeneity within the leukemic cell population. Methods are needed to ascertain the uniqueness of the ALL methylome in the presence of normal cells when bone marrow or peripheral blood samples from ALL patients are analyzed in bulk [24, 25] . In combination with recent reductions in DNA sequencing costs, single-cell sequencing offers a breakthrough for future analysis of DNA methylation in single cells from heterogeneous tumor populations [26, 27, 28] .
DNA methylation in ALL cells
Methylation of cytosine residues in CpG dinucleotides plays a pivotal role in the establishment of cellular identity by influencing gene expression [29] and is a widespread and common feature of all human cancers, including leukemias [30, 31] . The DNA methylomes of cancer cells have been found to contain large hypomethylated blocks and to display deregulation of the tightly controlled boundaries between methylated and unmethylated genomic regions [32] . Hypermethylation of CpG dense regions also known as CpG islands (CGIs) is the most systematically studied type of aberrant methylation across human cancers [31] . Accumulating evidence suggests that the pathogenesis and phenotypic characteristics of leukemic cells are the results of a combination of specific targeted and genome-wide alterations of DNA methylation [33, 34] .
The earliest studies to investigate aberrant DNA methylation in primary ALL cells analyzed CGIs nearby or in individual candidate genes. Although the small number of CGIs and patients included in these initial studies limits the interpretation of their results, they suggest that aberrant promoter methylation is associated with prognosis [35] , cytogenetic alterations [36] , cytogenetic subtype [37] , and relapse [38] . These early findings combined with technological advances outlined in Section 2 above, have spurred several groups to study aberrant changes in DNA methylation of ALL cells on a genome-wide scale. The design of these studies in terms of methods for DNA methylation analysis, number of ALL samples, type of control cells used, and their main results are summarized in Table 1 .
The consensus of the studies listed in Table 1 is that ALL cells generally have higher methylation levels in CpG sites that are located within CGIs than matched remission bone marrow and normal B/T-cells or hematopoietic precursor cells. Several independent studies discovered recurrent DNA methylation alterations, predominantly hypermethyated CGIs, which are observed across all genetic or immunophenotypic subtypes [39, 44, 8, 47, 49] . This finding suggests that some specific epigenetic changes are essential for leukemic transformation across all subtypes of ALL. Many of these changes occur de novo in regions that are co-occupied by the histone modifications H3K4me3 and H3K27me3 in embryonic stem cells, which indicates that leukemic transformation in ALL is assisted epigenetically via loss of plasticity and retention of an unlimited capacity of cellular self-renewal [47, 17] , as has been observed also in other hematological malignancies and solid tumors [31] .
Most DNA methylation studies published to date rely on targeted approaches with a focus on CGIs and thus do not present an unbiased view of the DNA methylome in ALL cells. Approaches that use NGS can in principle circumvent the bias of targeted analyses, but yet the few NGS studies from primary ALL cells offer somewhat conflicting results. Almamum et al. used an NGS approach where DNA fragments spanning methylated DNA regions are enriched and sequenced [50] . Their study comprising 20 ALL patients of various subtypes and pre-B cell controls found that CGIs in ALL cells had a larger number of methylated CpG sites than CGIs in control cells, but they also noted significant genomewide hypomethylation. Interrogation of two BCP-ALL genomes by WGBS revealed that one patient with the t(12;21)ETV6-RUNX1 subtype had similar global methylation levels as pre-B cells, while the second patient with a HeH subtype showed 4% lower total global methylation than pre-B cells [17] . WGBS of seven primary ALL patients of four different subtypes (T-ALL, t(12;21)ETV6-RUNX1, B-other, and normal karyotype) showed that each of the genomes were approximately 5% more abundantly methylated than control blood cells [18] . Based on discordant DNA methylation patterns in the WGBS reads, this study also concluded that the increase and large-variability of DNA methylation in CGIs is a result of stochastically occurring aberrant DNA methylation on individual chromosomes, as opposed to coordinated clonal methylation of the ALL cells. Notably this study did not find evidence for mega-base long segments of continuous hypomethylation, like those that have been frequently observed in other cancer types [60, 32] .
DNA methylation in ALL subtypes
DNA methylation studies of the recurrent ALL subtypes have identified subtype-specific signatures [41, 8, 47, 53, 17, 18] . Thus, it is wellestablished that each genetic subtype of ALL has a set of specific differentially methylated CpG sites that are useful for distinguishing between subtypes, similarly subtype-specific gene expression signatures measured by microarray-or NGS-based methods [61, 62] . Fig. 1 shows an example of subtype-specific DNA methylation patterning in established and emerging ALL subtypes. Subtype-specific DNA methylation signatures have been consistently reported across the ALL cohorts examined independently of the methods used to interrogate DNA methylation. These observations are perhaps not surprising since the subtype-defining primary genetic abnormalities define the key features of the cell and are ubiquitous across all clones. Such signatures have been used to design DNA methylation classifiers [48] and have potential use as future biomarkers. DNA methylation patterns in the BCP-ALL subtypes have been characterized in greater detail than in T-ALL, which often is viewed as a single subtype, although there are known subtypes of T-ALL [63] .
High hyperdiploidy (HeH)
HeH is a common subtype of pediatric ALL accounting for approximately 25% of diagnoses [64] . HeH is characterized by the nonrandom gain of chromosomes X, 4, 6, 8, 10, 14, 17, 18 and 21 for a total modal chromosome number greater than 50 [65] . The most striking epigenetic feature of HeH is a strong hypomethylation signature compared to the other ALL subtypes. One of the first DNA methylation studies in ALL described DNA hypomethylation hotspots and lower DNA methylation levels of aneuploid chromosomes in HeH patients [9] . Studies in larger cohorts reproduced the findings of hypomethylation, but did not observe preferential hypomethylation of trisomic chromosomes [8, 47, 53] . Furthermore, WGBS revealed a 4.4% lower genomewide CpG methylation level in one HeH patient than in normal pre-B cells [17] . Whole genome sequencing suggests that chromosomal gains are early driving events in HeH pathogenesis [66] . Because the DNA methylation profiles are so similar between patients harboring various combinations of chromosomal aneuploidies, it is plausible that the subtype-specific methylation signatures may predate or have occurred simultaneously as the chromosomal gains [48] .
t(12;21)/ETV6-RUNX1
The ETV6-RUNX1 fusion gene is detected in approximately 20% of ALL diagnoses and is a favorable prognostic marker [64] . CGI-centric experimental designs have shown a bias towards hypermethylation of this subtype [43, 8] , whereas studies using 450k BeadChips and WGBS revealed relatively equal numbers of differentially methylated CpG sites with higher and lower DNA methylation levels in patients with ETV6-RUNX1 when compared to normal blood cells [45, 47, 53, 18] . There is a generally good overlap between the differentially methylated genes in this subgroup. Of note, IGF2BP1, EPOR, FUCA1, and HLA-DPB1 were found to be hypometylated and have increased mRNA expression in ETV6-RUNX1 in four independent studies [45, 8, 47, 49] .
KMT2A-r
Lysine-specific methyl transferase 2A (KMT2A), also known as MLL1, is a promiscuous gene with over 80 different gene-fusion partners [67] . KMT2A rearrangements (KMT2A-r) are detected in 5-6% of ALL cases, most frequently in infants (1 < year), which comprise a distinctive disease entity with an aggressive disease with poor prognosis [68] . Infants with KMT2A-r exhibit few additional genetic abnormalities [69] , but display typical DNA methylation profiles, both as a subgroup distinct from other BCP-ALL subgroups, and within the KMT2A-r subgroup depending on the fusion partner [40, 58] . Two independent studies have shown that infants with t(11;19) and t(4;11) translocations differ from each other based on their DNA methylation pattern, yet both have increased DNA methylation in relation to normal bone marrow. It was also observed that samples from patients with t (9;11) resembled normal bone marrow samples [40] . These findings suggest that the DNA methylation pattern might underlie functionally relevant changes depending on the translocation partner of KMT2A.
t(1;19)/TCF3-PBX1
The translocation t(1;19)(q23;p13.3) resulting in the TCF3-PBX1 fusion gene is observed in approximately 4% of ALL cases and is associated with an intermediate risk [64] . According to DNA methylation analysis using 450k BeadChips the t(1;19)-specific DNA methylation signature is mostly hypomethylated [47, 53] . However, as determined by the HELP assays based on restriction site cleavage and ligation-assisted PCR, a subtype-specific signature in t(1;19) patients displayed nearly equal amounts of hyper-and hypomethylation [8] .
dic(9;20)
The chromosomal aberration dic(9;20)(p13.2;q11.2) occurs in up to 5% of BCP-ALL cases [70] . The translocation results in the loss of chromosome arms 9p and 20q with heterogeneity of the breakpoint, Table 1 Large-scale DNA methylation studies in pediatric ALL. Study Method ALL subtype (n patients)
Non-leukemia controls (n)
Main result
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Hypodiploid ( which in some cases produces a fusion gene involving PAX5 [71] . Besides studies on fusion genes, dic(9;20) has been a less frequently studied molecular subtype of BCP-ALL and it is uncertain whether the oncogenic mechanism underlying the dic(9;20) subtype is a gene fusion, loss of DNA from 9p and 20q, or a combination of both [72] . Only two independent studies have analyzed DNA methylation in dic(9;20) cases as a unique molecular entity and these studies agree that dic(9;20) displays a preferentially hypermethylated pattern [47, 53] .
t(9;22)/BCR-ABL1
Philadelphia chromosome (Ph+) or t(9;22)BCR-ABL1 is detected in 3-5% of pediatric ALL cases [64] . BCR-ABL1 is a prognostic indicator of an adverse disease and a biomarker for targeted therapy with imatinib or dasatinib [73] . Like other subtypes of ALL, patients with BCR-ABL1 can be distinguished by subtype-specific DNA methylation profiles. However, only 271 subtype-specific differentially methylated CpG sites in 36 genes were detected in BCR-ABL1, whilst other ALL subtypes typically displayed ∼2000 differentially methylated CpG sites [47] and in a follow-up study of the same patients, BCR-ABL1 was the most difficult subtype of ALL to classify based on DNA methylation [48] . In another study, 365 differentially methylated regions were described in BCR-ABL1, which is a similar number as in other subtypes [8] . Unlike most of the other BCP-ALL subtypes, the effect on DNA methylation by the BCR-ABL1 fusion protein is most likely indirect, as it does not involve direct aberration of transcription factors or histone modifications. Both of the studies mentioned above included 19 patients, but the method used to determine the DNA methylation levels differed (HELP and 450k, respectively). Thus the DNA methylation signatures for BCR-ABL1 need to be further clarified.
iAMP21
Intra chromosomal amplification of chromosome 21 (iAMP21) occurs in approximately 2% of ALL diagnoses [1] . The unifying feature of all iAMP21 cases is the amplification of the RUNX1 locus on chromosome 21, which is readily identifiable by FISH. This subtype was initially associated with high risk of relapse, but with intensified treatment protocols the prognosis has improved [73] . Given the low incidence of this subtype, our group has been the only one to report DNA methylation patterns specifically for this group [47, 48] . Interestingly, in our DNA methylation classifiers, we found that all iAMP21 cases classified both as HeH and iAMP21, and thus there is an overlapping signature between the iAMP21 and HeH cases, a pattern that is also seen based on unsupervised hierarchical clustering (Fig. 1) . Given that most HeH cases have extra copies of chromosome 21, it is likely the source of the methylation signature, but given the low number of patients (n = 8) analyzed, additional studies are needed.
Hypodiploidy
Hypodiploidy is defined based on a reduced number (< 45) of chromosomes and occurs at a frequency of 1-2% of ALL cases [64] . The modal number of chromosomes allows further classification of hypodiploidy into high hypodiploidy (40-44 chromosomes), low hypodiploidy (31-39 chromosomes), and near-haploidy (25-30 chromosomes). Only a single DNA methylation study has specifically addressed hypodiploid ALL and shown that the patients cluster together depending on the modal chromosome number per cell. In this study, like in HeH, the differences in methylation levels did not appear to arise from the chromosomal copy number [54] .
T-ALL
Compared to BCP-ALL, T-ALL has a worse outcome. Despite increasing knowledge of genetic aberrations in ALL, there are currently no other known reliable molecular genetic markers than minimal residual disease (MRD) for identifying patients with higher risk of relapse specifically in T-ALL [74] . The CpG island methylator phenotype (CIMP), defined by extensive DNA hypermethylation of cytosines within CGIs, has been documented in many cancers, including T-ALL [75, 76] . CIMP status can be denoted as CIMP+ or CIMP-, for high or low DNA methylation levels, respectively. T-ALL patients with CIMPhad significantly worse outcome compared to CIMP+ cases [46] and CIMP classification appears to predict relapse independently of MRD [56] . This pattern has been observed in relatively small T-ALL sample sets and needs to be replicated in larger, prospective cohorts before it can be implemented in clinical routine for treatment decisions. The question also remains if CIMP contributes to leukemogenesis or if is it merely a surrogate for epigenetic deregulation or cell proliferation in this subtype [76] .
DNA methylation signatures in emerging BCP-ALL subtypes
The group of patients without an established subtype-defining abnormality is collectively referred to as B-other. There remains a great Fig. 1 . Hierarchical clustering of primary ALL samples (GSE49031) with known subtype based on the methylation levels of the 1000 most variable CpG sites in the dataset [47] . The patients are color-coded by cytogenetic subtype and are clustered along the horizontal axis and the CpG sites are clustered along the vertical axis. In the heatmap, blue indicates low, yellow indicates intermediate, and red indicates high DNA methylation levels.
deal of heterogeneity in this group, but recent transcriptome sequencing studies discovered a network of recurrent fusion genes that in some cases identify the pathogenetic change and define new, prognostically relevant subtypes.
Our group described a subset of B-other patients with DNA methylation signatures akin to t(12;21)ETV6-RUNX1, but that were negative for the ETV6-RUNX1 fusion gene by FISH or PCR [48] . Such ETV6-RUNX1-like cases have also been described based on gene expression data [3] . Transcriptome sequencing studies of ETV6-RUNX1-like cases has since identified several, previously unknown in-frame fusion genes frequently involving ETV6 and another gene, including CBX3, AK125726, BORCS5, NID1, or PMEL [3, 77] . Similarly, ERG-altered "Bother" ALL cases have a DNA methylation signature distinct from other ALL subtypes [8] . Recently, rearrangements with the DUX4 gene (IGH-DUX4 or DUX4-ERG) were recognized as the initiating event in leukemic transformation in this emerging subgroup previously defined by ERG-alterations [3, 4] . Patients with DUX4 rearrangements along with another newly described group characterized by ZNF384 rearrangements also harbor distinct subtype-specific DNA methylation patterns [77] .
PAX5 on chromosome 9p is one of the most frequently altered genes in ALL. A rare subgroup of B-other patients harboring der(9)t(9;14) PAX5-ESRRB also displays distinct DNA hypomethylation in comparison to known BCP-ALL subtypes, including patients with other types of PAX5 gene fusions [57] . It is likely that most groups of cases within the B-other group with recurrent, leukemia-initiating genetic aberrations will have distinctive DNA methylation patterns.
Several independent studies have identified a distinct subgroup among the patients with BCP-other that lack the BCR-ABL1 translocation, but yet have a similar expression signature as BCR-ABL1 positive cases [78, 79, 80] . This group, referred to as BCR-ABL1-like, is now recognized as a new leukemia entity by WHO classification and may comprise as many as 8% of ALL patients, as has been reviewed in detail elsewhere [73, 1, 64] . These patients have several genomic features in common, like rearrangement or mutation of CRLF2, ABL1, ABL2, PDGFRB, JAK2, EPOR, etc. To our knowledge, no study has yet reported a BCR-ABL1-like DNA methylation signature, but this would be an important avenue for future research.
Relationship between DNA methylation and gene expression
Methylation of CpG sites in gene promoter regions has been found to correlate with gene expression in primary ALL cells. This is convincingly illustrated by a quantitative correlation between methylation levels of CpG sites in promoter regions and bidirectional allele-specific gene expression (ASE) observed for a subset of genes with large variability in DNA methylation levels [11] . This finding suggests that bidirectional ASE occurs as a consequence of CpG site methylation that is randomly distributed between the two chromosomes and causes allele-specific silencing or reduction of the expression of one of the alleles and is in agreement with observations from WGBS data from ALL cells [18] . The relationship between DNA methylation and gene expression is however complex, with multiple other epigenetic factors than DNA methylation that affect gene expression, like non-coding RNAs and chemical modification of histone proteins in regulatory (enhancer) regions of the genome. The subtype-specific DNA methylation changes in ALL are more frequently localized to enhancer regions and are associated with changes in gene expression, in contrast to the core set of differentially methylated CpG sites that are shared across ALL subtypes [8, 47] . Aberrant de novo DNA methylation in enhancers is associated with down-regulation of enhancer-derived RNA (eRNA) in BCP-ALL [51] and furthermore the ETV6-RUNX1 fusion protein alters the expression of eRNAs in enhancers containing RUNX1 binding motifs [81] .
Similarly to protein coding RNA expression, long-non-coding (lnc) or antisense RNAs are also differentially expressed in subtype-specific patterns [62, 82, 83, 84] . Moreover, aberrant expression of lnc antisense RNAs in BCP-ALL have been found to be associated with DNA hypermethylation [52] . Similarly as for lncRNAS, miRNA expression is common in ALL with subtype-specific signatures in most subtypes (reviewed in [33] , which is exemplified by a study demonstrating a specific miRNA expression signature in patients harboring DUX4-rearrangements (ERG deleted) [85] .
6. DNA methylation and relapse of ALL Although the survival rate for patients with pediatric ALL treated on modern protocols is high (> 90%), the outcome of ALL patients that relapse is poor [1] . Thus it would be highly beneficial if new biomarkers that predict relapse of ALL at diagnosis could be identified. As DNA methylation marks cellular states and is reversible, DNA methylation has good potential both as biomarker and as a potential treatment target.
DNA methylation as biomarker for prediction of relapse in ALL
Several studies have attempted to use DNA methylations signatures that are detectable at diagnosis for predicting relapse of ALL [40, 41, 46, 47, 86, 56, 59] . However, interpretation of the results from these studies is hampered by the minimal overlap of the DNA methylation signatures detected or CpG sites analyzed and by the low number of ALL patients in each study, subtype, or treatment group. Few studies have attempted replication of previous finings, or replication has failed [53] . An exception is a study on T-ALL that replicated a CpG island methylator phenotype (CIMP) signature in two independent, although relatively small sets of Nordic T-ALL patients that were treated on different protocols [46, 56] . One common finding in most of these studies is that the patients with lower methylation levels at diagnosis were more likely to relapse, compared to patients that escaped relapse. Examples of such findings are the T-ALL CIMP-negative signature of 1347 CpG sites [46, 56] and hypomethylation signatures based on small sets of genes (< 30) in HeH, ETV6-RUNX1, KMT2A-r, and BCR-ABL1 subgroups [41, 47] . One reason for the lack of reproducible prediction of relapse based on DNA methylation signatures at diagnosis could be that the clones which evolve to relapse are present at diagnosis only as minor clones at varying amounts in different patients and therefore do not expose a strong DNA methylation signature. Other reasons could be additional cellular heterogeneity of normal cells present in the sample that dampen the signatures, the different treatment protocols used across studies, or the relatively small cohorts examined.
Differential DNA methylation at diagnosis and at relapse of ALL
Matched cell samples collected at diagnosis and at relapse from ALL patients have been analyzed in three ALL cohorts using Infinium BeadArrays to evaluate differences in the methylome of ALL cells prior to and after therapeutic intervention [42, 47, 55] . The first study measured DNA methylation differences at diagnosis and relapse in 33 BCP-ALL cases and found higher DNA methylation levels in CGIs at relapse [42] . Genes of interest for relapsed ALL that emerged from this study included CDKN2A, COL6A2, PTPRO, and CSMD1. The second study involving 27 paired samples from diagnosis-relapse ALL patients of multiple subtypes replicated these findings [47] . An additional finding in the second study was that similarly to a common DNA methylation signature observed in ALL cells independently of cytogenetic subtype, the relapse-associated CpG sites overlapped with bivalent epigenetic marks of chromatin states and with genes regulated by REST, SOX2, NANOG, and OCT4 [47] . Conversely, in the third study where paired diagnosis-relapse samples from 13 T-ALL patients were analyzed, hypomethylation of promoter regions was more frequent than hypermethylation in relapsed samples [55] . Additional studies specifically focusing on T-ALL are needed to confirm this finding.
Chromatin modifications as epigenetic marks in ALL
Posttranslational modifications of histone proteins that together with DNA constitute the chromatin of each cell play an important role for temporal and cell-specific regulation of gene expression. Dynamic modification of chromatin as a consequence of interaction between histone marks and DNA methylation is likely to play a role for the malignant transformation of normal hematopoietic precursor cells into ALL cells. Chemical modifications of histone proteins as epigenetic marks have been less studied in ALL than DNA methylation (reviewed in [87] ), probably due to the technically more demanding methods for cell sampling and detection of histone marks. On the other hand the recent rapid development of NGS technologies have enabled identification of somatic mutations in ALL by comparison of matched tumor and normal DNA samples from ALL patients, either by analyzing panels of cancer genes, the entire coding region (exome) or whole genomes of the patients [88, 89, 90, 91, 92, 69, 55, 93, 54, 94, 21, 95, 22, 87] . Compared to other cancers, ALL genomes typically harbor few somatic mutations, but somatic alteration by mutation or translocation of genes encoding chromatin modifier genes that introduce or erase epigenetic marks from chromatin are enriched in ALL [96] .
The most frequently altered genes in ALL involved in epigenetic regulation are KMT2A, CREBBP, EP300, ASXL1, NSD2, SETD2, KMT2D, ATRX, and members of the Polycomb repressive complex 2 (PRC2) [88, 89, 91, 92, 94, 21, 95, 22, 87] . Somatic point mutations or small insertion-deletions (indels) occur across most subtypes of ALL, and do not appear to be mutually exclusive or enriched to any specific subtype, with the exception of the higher incidence of PRC2 mutations in T-ALL [96] . On the contrary, in-frame fusion genes involving KMT2A, CREBBP, and EP300 delineate specific subgroups of BCP-ALL with specific molecular and clinical phenotypes [1] . Mutations in DNA methyltransferases, on the other hand, appear to be rare in ALL [97, 21] .
KMT2A-r (MLL rearrangements) are a prototypic example of leukemia driven by deregulation of epigenetic processes, in this case by a fusion protein that disrupts the normal function of KMT2A, a H3K4-specific methyltransferase. In infants with the KMT2A-r subtype, few or perhaps no additional somatic coding mutations or copy number aberrations are required to cause overt leukemia, and thus the KMT2A fusion protein is thought to be a powerful cancer driver gene [69] . The KMT2A-AF4 fusion gene resulting from the translocation t(4;11) (q21,q23) is the most common KMT2A rearrangement in infant-ALL [1] . The downstream targets of KMT2A-AF4 have been characterized genome-wide in ALL cell lines by chromatin immunoprecipitation coupled with NGS [98] . The fusion protein binds to fewer genomic regions than wild-type KMT2A and extensive chromatin remodeling occurs in the KMT2A-AF4-bound regions, which results in large domains of aberrant H3K79 methylation However, KMT2A fusion proteins retain the ability to bind HOX genes and other promoter regions and are associated with enhanced gene expression [99] . Recurrent mutations in KMT2A along with KMT2D (MLL2), and KMT2C (MLL3) have been identified in ALL patients of various subtypes [21, 22] .
The BRD9-NUTM1 fusion gene resulting from t(5;15)(p15;q14) has been described in two infant-ALL cases negative for KMT2A-r to date [69, 48] . BRD9 is one of the less studied bromodomain (BRD)-containing proteins, but it likely functions in chromatin remodeling and regulation of gene expression and has recently been implicated in acute myeloid leukemia [100] . NUTM1 enhances the histone acetyltransferase activity of EP300 and is well known for its fusion with BRD4 in an aggressive malignancy called NUT midline carcinoma [101] . Interestingly, sporadic ALL cases with other NUTM1 fusion genes have been described in recent transcriptome sequencing studies (IKZF1-NUTM1, AFF1-NUTM1, ZNF618-NUTM1) [3, 6] . These recent findings identify a rare subset of ALL patients who may benefit from targeted small molecule inhibitors [102] .
Loss of function mutations in the CREBBP (CBP) gene have been observed in 18% of relapsed ALLs, particularly in the HeH subgroup [88] . EP300 (p300) is a CREBBP homolog with loss of function mutations in relapsed BCP-ALL [21] and in an aggressive subtype referred to as early T-cell precursor ALL (ETP-ALL) [90] . ZNF384 rearrangements have recently been described in a new subtype of BCP-ALL in which up to 80% of the patients have a mutation or translocation involving an epigenetic regulating gene [5, 6] . The fusions between ZNF384 and CREBBP or EP300 in this subtype result in dominant-negative loss of histone lysine acetyltransferase activity, which results in a global reduction of histone acetylation, and increased sensitivity to histone deacetylase inhibitors in in vitro assays [6] . Hense, a pattern is emerging in ALL where the genes with epigenetic functions that harbor recurrent single nucleotide variants (point mutations) or small indels and are also involved in gene fusions. Examples in addition to those described above include CBX3 mutations at relapse [103] and the ETV6-CBX3 fusion gene [48] and ASXL1 mutations and the RUNX1-ASXL1 [48] and NOL4L-ASXL1 [6] fusion genes.
Mutations in the genes encoding the three core subunits of the polycomb repressive complex 2 (PRC2), which methylates H3K27, have also been described in ETP-ALL [104, 90] . These genes include embryonic ectoderm development (EED), enhancer of zeste 2 (EZH2), and suppressor of zeste 12 (SUZ12). The EZH2 promoter is hypermethylated in T-ALL patients, however no promoter methylation changes were identified for the SUZ12 or EED genes [95] . Moreover, disruption of EZH2 is sufficient to induce T-ALL in mice [105] . Contrary to the function of H3K27 methylation, loss of function mutations in lysine demethylase 6A (KMT6A, also known as UTX), which specifically demethylates lysine 27 of histone H3, have also been observed in T-ALL [96, 106] . Interestingly, KMT6A mutated leukemias appear to be sensitive to treatment with an H3K27me3 inhibitor in an in vitro assay [107] .
Given that somatic mutations in ALL occur frequently in genes encoding epigenetic regulators, it is surprising that chemical modifications of histone proteins have not been mapped systematically on a genome-wide scale in primary ALL cells nor have the consequences of somatic mutations in epigenetic regulator genes on posttranslational modification of histone proteins been thoroughly examined. However, deregulated H3K9ac [108] , global acetylation [109] , and increased histone deacetylase activity [110] have been observed in ALL cells. Recent mechanistic studies in cell lines or mouse models have also linked perturbed patters of histone modifications to leukemogenesis. For example, an association between somatic alteration of the histone deacetylase gene KDM5C and increased global levels of H3K4me3 has been observed in a murine model of ETV6-RUNX1 driven ALL [111] . In another study, the chromatin mark H3K36me2 that is methylated by the ASH1L histone methyltransferase was linked to MLL-associated leukemogenesis in a human leukemia cell line, while KDM2A, which is a H3K36me2 demethylase and Polycomb group silencing protein antagonizes MLL-associated leukemogenesis [112] . Importantly, the Blueprint Consortium (www.blueprint-epigenome.eu) for mapping human blood cell epigenomes [113] has recently made available genome-wide data on histone modifications from primary ALL cells from 15 B-cell precursor ALL patients via the European Genome-Phenome Archive (accession #EGAD00001002421). Using this data, a regulatory mechanism for hereditary risk of HeH ALL has been proposed. A risk allele located in an enhancer element on chromosome 10p21.2 marked by H3K4me1, H3K4me3, and H3K27ac disrupts RUNX3 binding and reduces ARID5B expression, which in turn could arrest normal lymphocyte development leading to leukemia [114] . The data from Blueprint made available to the research community will be a valuable data source for future epigenetic studies in ALL.
Future perspectives and conclusions
The results from the studies discussed herein provide evidence for the importance of epigenetic alterations in pediatric ALL and their possible implications for the development of ALL, disease progression, and relapse. Combined with the heterogeneity of the cytogenetic subtypes of ALL, the characteristic patterns of DNA methylation and other epigenetic features render almost every patient unique. This heterogeneity poses challenges for diagnosis and treatment stratification. On the other, hand DNA methylation is highly informative regarding the cellular origin of the leukemia in each patient and the cytogenetic features underlying leukemogenesis. Moreover, DNA methylation is stable and easily detectable by relatively simple assays even in degraded DNA and historical biobanked samples of variable quality. Taken together these characteristics render epigenetic alterations, and especially DNA methylation excellent biomarkers for ALL.
The studies on epigenetics in primary ALL cells have so far been dominated by analysis of DNA methylation and more recently by the overrepresentation of mutations in epigenetic regulator genes. Collectively, the studies described above emphasize the importance of epigenetic control in leukemogenesis, but the phenotypic consequences of these mutations remain largely uncharacterized in primary ALL patients. A challenge for the future will be to translate our understanding of the relationship between mutations or gene fusions involving chromatin modifier genes, specific DNA methylation changes, and patterning of histone modifications in primary ALL cells into new therapeutic approaches.
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